MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- The number of subjects in Cohort A with serious adverse events during radiation.
研究概览
简要总结
This study is a prospective, open-label, phase I design.
详细描述
Study Rationale: There are limited studies evaluating real-time adaptive radiation therapy for locally advanced (Stage I-III) rectal adenocarcinoma with the goal of accomplishing organ preservation. We are testing higher doses of radiation therapy, using a novel method of real-time adaptive MRI-based radiation therapy treatment.
Hypothesis: We hypothesize that adaptive magnetic resonance (MR) -guided radiation therapy will result in acceptable toxicity and that a maximum-tolerated dose can be determined in a phase I setting.
Intervention Description: The intervention in this circumstance is higher doses of radiation therapy focused within the tumor given using adaptive MR guidance. Radiation Doses being applied in this study:
Cohort A- 64 Gy over 32 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to total dose of 64 Gy over 32 total fractions.
Cohort B- 68 Gy over approximately 34 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 68 Gy over 34 total fractions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed (histologic or cytological), adenocarcinoma of the rectum.
- •Determined on staging evaluation to be clinical stage I, II or III.
- •No concerning unequivocal or biopsy-proven metastatic disease. Patients are eligible with either no evidence of distant metastatic disease, or "equivocal" evidence of distant metastatic disease, as judged by the multidisciplinary tumor board. This "equivocal" definition can include small lung or liver lesions that are not able to be radiographically characterized otherwise.
- •Eastern Cooperative Oncology Group (ECOG) status 0-2 within 45 days of study entry.
- •History/physical examination, including collection of weight and vital signs within 45 days prior to start of treatment.
- •MR of the rectum is mandatory for staging and follow-up.
- •Chest CT scan within 45 days prior to study entry.
- •Radiation treatment planning abdominal CT. A mandatory pelvic MR will be done as a simulation (SIM) (ideally with interpretation). The CT SIM will not be done with interpretation. Ability to undergo abdominal MR scans for staging and radiation planning and follow-up is mandatory.
- •Laboratory values (CBC, Chem24) 45 days prior to treatment as follows:
- •Carcinoembryonic antigen (CEA) (any value).
- •Absolute neutrophil count (ANC) ≥ 1,000 cells/mm
- •Platelets ≥50,000 cells/mm
- •Hemoglobin ≥ 8.0 g/dl. (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.)
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 4 x upper limit of normal.
- •Total bilirubin < 2 x upper normal mg/dL.
- •Alkaline phosphatase < 4 x upper limit of normal.
- •Not on hemodialysis.
- •Ability to swallow oral medications.
- •Patients must be determined by medical oncology to be a candidate for systemic chemotherapy.
- •Patients must provide study-specific informed consent prior to study entry.
- •Negative serum pregnancy test (if applicable).
- •Women of childbearing potential and male participants who are sexually active must practice adequate contraception.
排除标准
- •Biopsy-proven distant metastatic disease or high clinical concern for metastatic disease and tumor conference consensus of stage IV disease.
- •Prior invasive malignancy (except nonmelanomatous skin cancer, noninvasive breast cancer (DCIS), or prostate cancer under active surveillance). Other malignancies are allowed if patient has been disease free for a minimum of three years
- •Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
- •Any major surgery within 28 days prior to study entry, except colonic stent placement, intestinal diversion without resection or vascular access insertion.
- •Severe, active comorbidity, defined as follows:
- •Unstable angina and/or congestive heart failure requiring hospitalization within the last six months.
- •Transmural myocardial infarction within three months prior to study entry.
- •Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- •Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration.
- •Uncontrolled malabsorption syndrome significantly affecting gastrointestinal function.
- •Any unresolved intestinal obstruction.
- •Acquired immune deficiency syndrome (AIDS), based upon current Centers for Disease Control and Prevention (CDC) definition. Note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because patients receiving antiretroviral therapy may experience possible pharmacokinetic interactions with required treatment medications, such as capecitabine.
- •Absence of any significant medical comorbidity which would preclude the consideration of major intestinal surgery.
- •Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during the course of the study and for women three months after study therapy is completed and for men six months after study therapy is completed. This exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
- •Participation in another interventional clinical treatment trial while on study (observational trials are permitted).
- •Patients taking nonprotocol-specified chemotherapy agents or immune-modulating agents for other medical conditions are not permitted to participate in this trial. Any medication questions should be reviewed by the PI.
- •Poor functional status such that patients are not able to be positioned for radiation treatments.
- •Gadolium allergy.
- •If age over 60, history of hypertension, diabetes or liver transplant, and glomerular filtration rate (GFR) at enrollment is < 30.
研究组 & 干预措施
Cohort A
Radiation dose: 64 Gy over 32 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to total dose of 64 Gy over 32 total fractions.
干预措施: Capecitabine (Drug)
Cohort A
Radiation dose: 64 Gy over 32 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to total dose of 64 Gy over 32 total fractions.
干预措施: Initial Dose of Radiation before Dose Escalation (Device)
Cohort A
Radiation dose: 64 Gy over 32 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to total dose of 64 Gy over 32 total fractions.
干预措施: FOLFOX (Drug)
Cohort B
Radiation dose: 68 Gy over approximately 34 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 68 Gy over 34 total fractions.
干预措施: Capecitabine (Drug)
Cohort B
Radiation dose: 68 Gy over approximately 34 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 68 Gy over 34 total fractions.
干预措施: Initial Dose of Radiation before Dose Escalation (Device)
Cohort B
Radiation dose: 68 Gy over approximately 34 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 68 Gy over 34 total fractions.
干预措施: FOLFOX (Drug)
Cohort C
Radiation dose: 72 Gy over 36 total fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 72 Gy over 36 total fractions
干预措施: Capecitabine (Drug)
Cohort C
Radiation dose: 72 Gy over 36 total fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 72 Gy over 36 total fractions
干预措施: Initial Dose of Radiation before Dose Escalation (Device)
Cohort C
Radiation dose: 72 Gy over 36 total fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 72 Gy over 36 total fractions
干预措施: FOLFOX (Drug)
Cohort A
Radiation dose: 64 Gy over 32 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to total dose of 64 Gy over 32 total fractions.
干预措施: Cohort A: Dose Escalation Radiation (Device)
Cohort B
Radiation dose: 68 Gy over approximately 34 fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 68 Gy over 34 total fractions.
干预措施: Cohort B: Dose Escalation Radiation (Device)
Cohort C
Radiation dose: 72 Gy over 36 total fractions, prophylactic nodes treated to 50 Gy over 25 fractions, boost to tumor and radiologically positive nodes to 72 Gy over 36 total fractions
干预措施: Cohort C: Dose Escalation Radiation (Device)
结局指标
主要结局
The number of subjects in Cohort A with serious adverse events during radiation.
时间窗: Up to 11.5-week period
This will be measured by NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grades 3, 4 and 5 will be serious.
The number of subjects in Cohort B with serious adverse events during radiation.
时间窗: Up to 11.5-week period
This will be measured by NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grades 3, 4 and 5 will be serious.
The number of subjects in Cohort C with serious adverse events during radiation.
时间窗: Up to a 12.1-week period.
This will be measured by NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grades 3, 4 and 5 will be serious.
次要结局
- The number of subjects in Cohort A with a complete clinical response (CCR) to treatment.(31.5 weeks)
- The number of subjects with dose-limiting toxicities in Cohort B.(11.5-week period)
- The number of subjects in Cohort B with a complete clinical response (CCR) to treatment.(31.5 weeks)
- The number of subjects in Cohort C with a complete clinical response (CCR) to treatment.(32.1 weeks)
- The number of subjects in Cohort A with a noncomplete response (NCR) to treatment.(31.5 weeks)
- The number of subjects in Cohort B with a noncomplete response (NCR) to treatment.(31.5 weeks)
- The number of subjects in Cohort C with a noncomplete response (NCR) to treatment.(32.1 weeks)
- Circulating tumor deoxyribonucleic acid (ctDNA)(Baseline, 12.1 weeks, 32 weeks, one year and two years.)
- Change from baseline in the EQ-5D-SL quality of life questionnaire(Baseline and up to 12.1 weeks.)
- The number of subjects with dose-limiting toxicities in Cohort C.(12.1- week period)
- Change from baseline in the Wexner Fecal Incontinence Score(Baseline and up to 12.1 weeks.)
- The number of subjects with dose-limiting toxicities in Cohort A.(11.5-week period)
- Change from baseline in the Memorial Sloan Kettering Bowel Function Index (MSKCC BFI) Score(Baseline and up to 12.1 weeks.)
研究者
William Hall
Professor
Medical College of Wisconsin